This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

saline nasal sprays for respiratory tract infections

Authoring team

Nasal saline in upper respiratory tract infections (URTI)

  • saline can be delivered to the nose as a large‐volume wash using reservoir pots and tubing, or in a small volume via spray devices that deliver a fine mist or jet of saline into the nose
  • usual concentration is 'normal saline', which approximates an iso‐osmolar fluid
  • hypertonic saline is sometimes used to deliver a stronger concentration of fluid to the nasal cavity and sinuses
  • saline irrigation of the nose is believed to alleviate URTI symptoms by clearing excess mucus, reducing congestion and improving breathing
    • is thought to improve mucociliary clearance by increasing the ciliary beat frequency
    • in addition to relieving sinonasal symptoms, saline irrigation may remove infectious material from the sinuses and reduce cough associated with postnasal drip

A systematic review concluded that (1):

  • limited data from five randomised controlled trials (RCTs) suggest that saline nasal irrigation may have some benefit in patients with acute upper respiratory tract infections (URTIs)
    • nasal irrigation with saline is a safe treatment that may be mildly beneficial to some patients
  • note that some participants experienced minor discomfort, no serious side effects were identified

Follow-up of Immune defence trial found Vick’s First-Defence (VFD) spray (2 sprays per nostril 6 times a day) and saline nasal spray (same dosing) both reduced illness days (mean 18 days for both vs 22 days usual care) and a website promoting self-care reduced incident infections (2):

  • immune defence trial documented short term impacts on RTIs for nasal sprays, and a stress-management and physical activity website
    • 12-month follow-up of a randomized open-label trial found that both nasal sprays (gel-based and saline) and a behavioral intervention reduced the severity and duration of RTIs compared to usual care
    • showed that all interventions reduced symptom severity and work-days lost, both spray groups reported lower intention to consult and fewer falls, and there were fewer antibiotic courses and practice visits with saline
      • among those with recurrent illness saline had the most impact on both recurrence and symptom days (respectively 0.93 (0.87,0.99), 0.70 (0.60,0.82))
      • headache were higher for VFD and lower for saline (7.8%, 3.4% respectively; 4.7% usual care)
  • study authors concluded:
    • widely available, inexpensive sprays and a website promoting self-care reduce the incidence, duration and/ or severity of RTIs and impact work-days lost and healthcare use

Reference:

  1. King D, Mitchell B, Williams CP, Spurling GK. Saline nasal irrigation for acute upper respiratory tract infections. Cochrane Database Syst Rev. 2015 Apr 20;2015(4):CD006821.
  2. Little P et al. 12-month follow-up of a randomized open-label trial found that both nasal sprays (gel-based and saline) and a behavioral intervention reduced the severity and duration of respiratory tract infections (RTIs) compared to usual care. BJGP October 24th 2025.

Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2025 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.